Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus

Rocket Pharmaceuticals (RCKT) incurred a loss of 62 cents per share in the fourth quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 71 cents. In the year-ago quarter, the company reported a loss of 64 cents per share.See the Zacks Earnings Calendar to stay ahead of market-making news.In the absence of any marketed product in its portfolio, Rocket Pharmaceuticals did not record any revenues in the fourth quarter.In the past year, shares of Rocket Pharmaceuticals have plunged ...